Ken Griffin Galera Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.14 - $0.27 $1,134 - $2,187	8,100 Added 368.18%	10,300 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.09 - $0.27 $27 - $81	-300 Reduced 12.0%	2,200 $0
Q3 2023 Nov 14, 2023	SELL	$0.17 - $3.0 $2,414 - $42,600	-14,200 Reduced 85.03%	2,500 $0
Q2 2023 Aug 14, 2023	SELL	$2.5 - $3.42 $64,750 - $88,578	-25,900 Reduced 60.8%	16,700 $52,000
Q1 2023 May 15, 2023	BUY	$1.48 - $2.68 $16,576 - $30,016	11,200 Added 35.67%	42,600 $109,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $133,464 - $177,288	-99,600 Reduced 76.03%	31,400 $46,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $18,860 - $34,440	-16,400 Reduced 11.13%	131,000 $228,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.34M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.